Simplex Trading’s Trevi Therapeutics TRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.82M Buy
97,557
+77,280
+381% +$1.12M ﹤0.01% 2145
2026
Q1
$242K Sell
20,277
-26,857
-57% -$301K ﹤0.01% 4069
2025
Q4
$590K Sell
47,134
-16,015
-25% -$185K ﹤0.01% 3139
2025
Q3
$577K Buy
+63,149
New +$474K ﹤0.01% 3644
2025
Q1
Sell
-24,913
Closed -$119K 9713
2024
Q4
$102K Buy
24,913
+15,272
+158% +$48.9K ﹤0.01% 5162
2024
Q3
$32K Buy
+9,641
New +$28.7K ﹤0.01% 6308
2023
Q2
Sell
-10
Closed 9962
2023
Q1
$0 Hold
10
﹤0.01% 10151
2022
Q4
$0 Buy
+10
New +$20 ﹤0.01% 10460

Other funds holding TRVI

Simplex Trading's TRVI Position: Q2 2026 in Review

Simplex Trading increased its Trevi Therapeutics (TRVI) stake by 381% in Q2 2026, buying an estimated $1.12M and bringing the position to 97,557 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2145.

Simplex Trading first reported a position in TRVI in Q4 2022 and has held it in 8 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Simplex Trading held 97,557 shares of Trevi Therapeutics worth $1.82M as of Q2 2026.
  • Simplex Trading bought 77,280 Trevi Therapeutics shares in Q2 2026, an estimated $1.12M.
  • Trevi Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #2145 holding.
  • Simplex Trading first reported a position in Trevi Therapeutics in Q4 2022 and has held it in 8 quarters since.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.